Related Experiment Video
Updated: Aug 7, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
HSV amplicon vectors for cancer therapy
Khalid Shah1, Xandra O Breakefield
1Center for Molecular Imaging Research and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA. kshah@helix.mgh.harvard.edu
Current Gene Therapy
|June 22, 2006
Summary
Herpes simplex virus (HSV) amplicon vectors offer a powerful platform for cancer gene therapy due to their large capacity and versatility. These vectors enable targeted delivery of therapeutic genes, enhancing anti-tumor immunity and treatment efficacy.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Herpes simplex virus (HSV) amplicon vectors are advanced tools for cancer treatment.
- They possess a large transgene capacity (up to 150 kb), allowing for multiple and large gene insertions.
- Methods for heritable transgene transmission via episomal replication or genomic integration have been developed.
Purpose of the Study:
- To explore the therapeutic potential of HSV amplicon vectors in cancer treatment.
- To highlight the versatility of these vectors in delivering various therapeutic agents and facilitating gene expression control.
- To investigate their utility in combination therapies and diagnostic applications.
Main Methods:
- Incorporation of therapeutic transgenes, including anti-angiogenic agents, immune enhancers, and apoptosis-inducing factors.
- Combination of amplicon vectors with oncolytic HSV vectors for broader therapeutic applications.
- Utilizing promoter manipulation for targeted gene expression and drug-regulated expression.
- Employing vectors for tumor vaccination via dendritic cell targeting.
- Converting tumor cells into packaging cells for generating other viral vectors.
- Exploring imaging modalities for monitoring gene delivery and therapeutic response.
Main Results:
- Demonstrated capacity to carry large transgenes and control their fate in host cells.
- Successful delivery of various therapeutic payloads, including inhibitory RNAs.
- Enhanced tumor vaccination through high infectivity of dendritic cells and intrinsic immune-enhancing properties.
- Capability to target both dividing and non-dividing tumor cells.
- Versatility in generating vectors in situ and monitoring treatment outcomes via imaging.
Conclusions:
- HSV amplicon vectors represent a highly adaptable and potent platform for cancer gene therapy.
- Their large capacity, targeted delivery, and immune-modulating properties offer significant therapeutic advantages.
- These vectors hold promise for combination therapies, in situ vector generation, and advanced imaging applications in oncology.
Related Concept Videos
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:51Mechanisms of Retrovirus-induced Cancers
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...